Rong Tao, MD & PhD
Shanghai Cancer Center · Fudan University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Rong Tao, MD & PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:53 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07678229 · BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCLRong Tao · recruiting · Extranodal NK/T-cell Lymphoma · study chair
- Ph2NCT07507318 · Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete RemissionRong Tao · recruiting · Diffuse Large B-Cell Lymphoma · study chair
- Ph1/Ph2NCT07502768 · Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell LymphomaRong Tao · recruiting · Extranodal NK/T-cell Lymphoma, NK/T-cell Lymphoma, Relapsed or Refractory NK/T-Cell Lymphoma · study chair
- Ph3NCT07300514 · Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell LymphomaFudan University · recruiting · Maintenance Treatment of Peripheral T-cell Lymphoma · principal investigator
- Ph2NCT04004572 · Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell LymphomaRong Tao · completed · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.